SeaStar Medical (ICU) Investor presentation summary

Mission and value proposition

• Aims to stop organ failure and save lives by neutralizing destructive hyperinflammation.

• SCD therapy is agnostic to disease state and protected by 34 U.S. and foreign patents.

• Holds FDA Breakthrough Device Designations for both ICU and clinical settings.

• Focuses on high gross profit margin and efficient commercialization.

• Demonstrated ability to preserve organ function and save lives.

Market opportunity and unmet need

• Adult AKI market estimated at $4.5B annually with ~200,000 patients; pediatric market at $100M with ~4,000 patients.

• Critically ill AKI patients have over 50% mortality and high risk of end-stage renal disease.

• QUELIMMUNE addresses high unmet need in pediatric AKI, with 50% mortality in multi-organ dysfunction cases.

• SCD therapy is the first and only therapy to neutralize hyperinflammation.

Clinical data and safety profile

• QUELIMMUNE showed 77% survival at Day 60 in pediatric AKI, with no device-related adverse events.

• SAVE Surveillance Registry data mirrors high survival rates and no device-related safety events.

• No device-related infections, immunosuppression, or serious adverse events across >150 patients in 6 studies.

• Adult AKI study outcomes consistent with pediatric studies, showing improved survival and reduced dialysis dependence.